3.83

0.90% -0.06

Nervgen Pharma Corp (NGEN)

Overview News Price History Discussions Forecast

Nervgen Pharma Corp stock is traded at $3.83, with a volume of 109.94K. It is down -0.90% in the last 24 hours and down -2.90% over the past month. NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Previous Close:

$3.89

Open:

$3.84

24h Volume:

109.94K

Relative Volume:

0.71

Market Cap:

$309.97M

Revenue:

Net Income/Loss:

$-31.64M

P/E Ratio:

-9.0629

EPS:

-0.4226

Net Cash Flow:

$-13.98M

1W Performance:

+6.20%

1M Performance:

-2.90%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$3.80

$3.95

1-Week Range:

$3.55

$3.95

52-Week Range:

$3.51

$5.9299

Nervgen Pharma Corp Stock (NGEN) Company Profile

Name

Nervgen Pharma Corp

Sector

Healthcare (1115)

Industry

Biotechnology (621)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

NGEN's Discussions on Twitter

Compare NGEN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NGEN Nervgen Pharma Corp	3.83	314.82M	0	-31.64M	-13.98M	-0.4226
VRTX Vertex Pharmaceuticals Inc	426.44	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	711.31	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.00	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.95	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	315.66	32.51B	5.36B	287.73M	924.18M	2.5229

Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	H.C. Wainwright	Buy

Nervgen Pharma Corp Stock (NGEN) Latest News

Apr 30, 2026

NervGen Pharma (NGEN) Stock Chart and Price History 2026 - MarketBeat

Apr 30, 2026

Top NervGen Pharma (NGEN) Competitors 2026 - MarketBeat

Apr 30, 2026

Apr 29, 2026

What is the current Price Target and Forecast for NERVGEN PHARMA (NGEN) - Zacks Investment Research

Apr 29, 2026

NERVGEN PHARMA (NGEN) - Zacks Investment Research

Apr 29, 2026

Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug - Streetwise Reports

Apr 29, 2026

Apr 28, 2026

H.C. Wainwright reiterates NervGen stock rating on new CFO hire By Investing.com - Investing.com India

Apr 28, 2026

H.C. Wainwright reiterates NervGen stock rating on new CFO hire - Investing.com UK

Apr 28, 2026

NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan - TipRanks

Apr 27, 2026

NervGen appoints Keith Vendola as chief financial officer - Investing.com UK

Apr 27, 2026

NervGen Pharma (NGEN) Stock Forecast and Price Target 2026 - MarketBeat

Apr 27, 2026

NervGen Pharma initiated with a Buy at H.C. Wainwright - TipRanks

Apr 27, 2026

NervGen Pharma appoints Keith Vendola as CFO - TipRanks

Apr 27, 2026

NGEN Initiated Coverage by HC Wainwright & Co. -- Price Target A - GuruFocus

Apr 27, 2026

NervGen appoints Keith Vendola as chief financial officer By Investing.com - Investing.com Australia

Apr 27, 2026

This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Apr 27, 2026

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer - The Manila Times

Apr 27, 2026

NervGen Pharma appoints new president & CEO - MSN

Apr 27, 2026

Apr 21, 2026

NervGen Pharma Corp. Common stock Stock Forecast Summary - Meyka

Apr 21, 2026

Apr 20, 2026